Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference

Rhea-AI Summary

Minerva Neurosciences, a clinical-stage biopharmaceutical company, will participate in Citi's 15th Annual BioPharma Virtual Conference on September 9, 2020, at 1:30 p.m. ET. The panel discussion focuses on "Emerging Therapies for Psychiatric Disorders." Investors can access the presentation live and on-demand via the company's website. Minerva’s product pipeline includes roluperidone for schizophrenia and seltorexant for insomnia, with additional projects targeting Parkinson’s disease.

WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in Citi's 15^th Annual BioPharma Virtual Conference on September 9, 2020 at 1:30 p.m. Eastern Time.  The panel in which the Company will participate is entitled “Emerging Therapies for Psychiatric Disorders.”

The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.  

About Minerva Neurosciences

Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376

 

FAQ

When will Minerva Neurosciences participate in the Citi BioPharma Conference?

Minerva Neurosciences will participate on September 9, 2020, at 1:30 p.m. ET.

Where can I watch the Minerva Neurosciences presentation from the conference?

The presentation will be accessible live and archived through the investor relations section of Minerva's website.

What is the focus of Minerva's panel discussion at the conference?

The panel discussion is focused on 'Emerging Therapies for Psychiatric Disorders.'

What are the main products in Minerva Neurosciences' pipeline?

Minerva's pipeline includes roluperidone for schizophrenia, seltorexant for insomnia, and MIN-301 for Parkinson's disease.

What is the stock symbol for Minerva Neurosciences?

Minerva Neurosciences is listed under the NASDAQ symbol 'NERV.'